Tesamorelin Acetate sourcing should not be treated as a simple price comparison. B2B buyers evaluating this SKU need to clarify the salt form, the molecular-weight basis, the purity basis, the documentation scope, the quote unit, format, and lead time before comparing offers. A quote that looks cheap on a USD/g or USD/vial basis often turns out to describe a different material form, a different purity basis, or a different documentation level.

This guide is written for qualified research and formulation buyers. It covers Tesamorelin Acetate as a research-use raw material only. It does not provide dosing, administration, reconstitution, or any human-use guidance, and WUMO Peptide is not affiliated with any branded tesamorelin drug product.

What Tesamorelin Acetate Is from a Sourcing Perspective

Tesamorelin (development code TH9507) is a synthetic 44-amino-acid analog of growth hormone-releasing hormone, GHRH / GRF(1-44), with a non-standard N-terminal trans-3-hexenoyl modification. From a sourcing perspective two things follow from that structure: it is a long peptide, so synthesis is demanding and genuine production is limited; and it is supplied as the acetate salt, so peptide content and assay must be read against the salt form, not just a purity percentage.

It is supplied here as a research-use raw material — bulk lyophilized powder by gram, or lyophilized vial format — for laboratory research and B2B sourcing projects.

Why Tesamorelin Sourcing Projects Stall — and How to Avoid It

Common buyer mistakes at the start of a project

  • Asking for the lowest USD/g or USD/vial number before confirming the salt form and purity basis.
  • Treating a "99%" headline as proof of identity, without an HPLC chromatogram or LC-MS result.
  • Comparing a bulk-powder quote against a filled-vial quote as if they were the same line item.
  • Accepting a generic COA that is not tied to the batch being quoted.

What to clarify before comparing quotes

  • Is the material acetate (CAS 901758-09-6) or free base (CAS 218949-48-5)?
  • Which molecular-weight basis does the COA use — free-base equivalent (~5135.9 Da) or acetate salt basis (~5196 Da)?
  • Is the quote per gram of bulk powder, or per filled vial at a stated fill strength?
  • Is purity stated separately from peptide content / assay?
  • What documentation comes with the lot, and is it batch-specific?

Tesamorelin Acetate Specification Fields Every B2B Buyer Should Review

Identity and structural parameters

  • Name and code: Tesamorelin Acetate (TH9507); class term GRF(1-44) / GHRH analog.
  • Sequence reference: 44-amino-acid GHRH(1-44) analog with N-terminal trans-3-hexenoyl modification.
  • CAS: 901758-09-6 (acetate) and 218949-48-5 (free base) — both appear in the market, so confirm which the lot is.

Quality parameters

  • Purity: >99.3% by HPLC, confirmed on a batch-specific COA.
  • Identity: LC-MS, with the observed mass reconciling to the stated basis.
  • Peptide content / assay: reported separately from purity, after water and counterion.

Salt form and counterion basis

Tesamorelin is supplied as the acetate salt. Acetate and water make up part of the salt's mass, so a gram of acetate salt contains less target peptide than a gram of free base. This is why content and purity are different questions, and why the molecular-weight basis on the COA matters.

Physical characteristics

  • Appearance: white to off-white lyophilized powder.
  • Format: bulk powder by gram, or lyophilized vial (2 / 5 / 10 mg, subject to batch).
  • Storage: recommended −20°C for long-term storage; follow batch-specific documentation.

The Two CAS Numbers and the Two Molecular Weights

This is the single point most quotes get wrong. "Tesamorelin" and "Tesamorelin acetate" are the same peptide in two forms: the free base (CAS 218949-48-5) and the acetate salt (CAS 901758-09-6, the form supplied here). The widely quoted ~5135.9 Da is the free-base equivalent; the acetate salt basis is around ~5196 Da. Neither number is "wrong" — what matters is internal consistency: the salt form, the stated molecular-weight basis, and the LC-MS observed mass must all reconcile. A COA that mixes the two CAS numbers without stating the salt form is a professionalism signal worth noting.

Documentation: What to Request, When, and Why

Certificate of Analysis (COA)

Request a batch-specific COA that matches the lot being quoted. It should carry a batch number, the salt form, purity, and the tests run on that lot.

HPLC purity report

Ask for the chromatogram, not just the percentage — with the method (column, mobile phase, gradient, wavelength, main-peak retention time, integration table) so the result can be reproduced on the goods you receive.

LC-MS or mass confirmation

The observed mass must reconcile with the stated basis. LC-MS is what confirms the molecule is Tesamorelin rather than a structurally related GHRH peptide such as sermorelin or CJC-1295.

SDS and specification sheet

Confirm SDS/MSDS availability for handling, and a specification sheet covering appearance, assay, and relevant limits.

For a deeper walkthrough, see our peptide COA, HPLC and LC-MS documentation review guide.

Red Flags Buyers Should Watch For

Documentation red flags

  • A "99%" claim with no chromatogram and no LC-MS.
  • A COA with no batch number, or one that does not match the quoted lot.
  • Salt form or molecular-weight basis not stated, so assay cannot be reconciled.
  • The same lab PDF reused across products or suppliers.

Quote and pricing red flags

  • A price far below the market for verified material — usually low purity, substitution, or repacked unknown stock.
  • A per-gram or per-vial number quoted before the material form and purity basis are agreed.

Supplier response red flags

  • Cannot state the salt form or discuss the N-terminal modification.
  • Defers all documentation to "on request" and never provides it.

Bulk Powder vs. Lyophilized Vial: Choosing the Right Format

Bulk lyophilized powder (by gram) suits formulation development, analytical method work, and projects that will fill or compound downstream under the buyer's own controls. Lyophilized vial format suits projects that need a defined fill strength and neutral or private-label packaging. The two are quoted on different bases, so confirm the format before comparing numbers. See our guide to vial fill amount, packaging and documentation.

Lead Time and Quote Basis: What the Numbers Actually Mean

Typical lead time for Tesamorelin Acetate is approximately 20 days, subject to batch availability and order scope. When you receive a quote, confirm the quote unit (per gram of bulk vs per filled vial), the purity basis behind it, the documentation included, and the packaging scope — so that two offers are genuinely comparable. Order quantity and project scope are confirmed during RFQ rather than published as a fixed figure.

How to Prepare a Stronger RFQ for Tesamorelin Acetate

A better RFQ states: the material and salt form (acetate, CAS 901758-09-6); required purity (>99.3% HPLC) and whether peptide content/assay is required; whether an HPLC chromatogram and LC-MS identity are required; the format (bulk by gram or vial at a stated fill); packaging and storage; and the intended use declaration (research use only). It does not need to include downstream dosing, protocols, or any human-use detail — those are out of scope for a raw-material RFQ.

Supplier Qualification Checkpoints

Score a supplier on whether it can state the salt form and molecular-weight basis, provide a batch-specific COA with HPLC and LC-MS, separate purity from content, and offer a report you can verify. Our peptide supplier qualification checklist covers the full method, and the closely related Sermorelin Acetate sourcing guide is a useful companion for GHRH-class projects.

What WUMO Reviews Before Issuing a Formal Quotation

Before quoting Tesamorelin Acetate, WUMO confirms the format (bulk or vial), purity basis (>99.3% HPLC), salt form (acetate) and molecular-weight basis, documentation scope (COA, HPLC, LC-MS, SDS), packaging, and lead time. Research-grade is standard; API-grade is available under a signed quality agreement, and a third-party verification report can be provided where authorized. To start, see the Tesamorelin Acetate product page or submit an RFQ.

Research use only. Not for clinical, therapeutic, compounding, injection, human, veterinary, food, or cosmetic use. WUMO Peptide is not affiliated with any branded tesamorelin drug product.